Search research articles
Contact Us
Filters
Showing results (101-110 of 119) with videos related to
Page
of 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 17, 2020
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment
A Fabi, R Bhargava, S Fatigoni, et al.
Cancer Treatment Reports
|
December 1, 1985
Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research
F Roila, M Tonato, C Basurto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 1991
Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales
F Roila, M Lupattelli, M Sassi, et al.
American Journal of Clinical Oncology
|
June 1, 1991
Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study
F Roila, E Boschetti, M Tonato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1987
Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research
F Roila, M Tonato, C Basurto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1989
Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research
F Roila, M Tonato, C Basurto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1991
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone
F Roila, M Tonato, F Cognetti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Reliability and validity of a quality of life questionnaire in cancer patients
E Ballatori, F Roila, C Basurto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 22, 2012
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
G Curigliano, D Cardinale, T Suter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 8, 2012
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
M Aapro, A Molassiotis, M Dicato, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 119) with videos related to
Sort By:
Page
of 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 17, 2020
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment
A Fabi, R Bhargava, S Fatigoni, et al.
Cancer Treatment Reports
|
December 1, 1985
Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research
F Roila, M Tonato, C Basurto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 1991
Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales
F Roila, M Lupattelli, M Sassi, et al.
American Journal of Clinical Oncology
|
June 1, 1991
Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study
F Roila, E Boschetti, M Tonato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1987
Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research
F Roila, M Tonato, C Basurto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1989
Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research
F Roila, M Tonato, C Basurto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1991
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone
F Roila, M Tonato, F Cognetti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Reliability and validity of a quality of life questionnaire in cancer patients
E Ballatori, F Roila, C Basurto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 22, 2012
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
G Curigliano, D Cardinale, T Suter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 8, 2012
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
M Aapro, A Molassiotis, M Dicato, et al.
Page
of 12